Business Context and Reporting Period
Dermata Therapeutics, Inc. (DRMA) filed a Form 8-K on March 25, 2025, reporting a notice of non-compliance with Nasdaq Capital Market listing standards. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
- Stockholders' Equity: Approximately $1.6 million (as reported in the 2024 Form 10-K).
- Required Minimum Equity: $2.5 million per Nasdaq Listing Rule 5550(b)(1).
- Alternative Compliance: The Company does not meet alternative standards for market value of listed securities or net income from continuing operations.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes and Listing Status
The Company received a letter from Nasdaq on March 25, 2025, stating it failed to meet the minimum stockholders' equity requirement. While the securities continue to trade on the Nasdaq Capital Market, the Company is currently non-compliant. No immediate delisting has occurred, but the status is contingent on regaining compliance.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 45 calendar days (until May 9, 2025) to regain compliance or submit a plan.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension until September 21, 2025.
- Delisting Risk: Failure to regain compliance by the deadline or failure to have a plan accepted could lead to delisting.
- Appeal Process: If delisting is threatened, the Company may request a hearing before an independent Hearings Panel for a potential 180-day extension.
- Management Action: The Company is evaluating courses of action and intends to submit a compliance plan timely, though there is no assurance of acceptance or success.
Investor Verification Checklist
- Verify the Company's current stockholders' equity and cash position to assess the feasibility of raising capital.
- Monitor the submission of the compliance plan to Nasdaq by May 9, 2025.
- Review the Company's 2024 Form 10-K for detailed financial statements regarding the $1.6 million equity figure.
- Watch for any announcements regarding a potential hearing request if the initial compliance deadline is missed.